Jacoby, J., Mahalingam, D., Alistar, A., Garmey, E., Kazmi, S., Mooneyham, T., Sun, L., Yap, T. A., Vu, P., Moser, J.

Phase 1 first-in-human dose-escalation study of IMSA101, a novel cyclic di-nucleotide STING agonist, for patients with advanced solid tumor malignancies

18 de June de 2025 by Jacoby, J., Mahalingam, D., Alistar, A., Garmey, E., Kazmi, S., Mooneyham, T., Sun, L., Yap, T. A., Vu, P., Moser, J.

Background
Despite progress in cancer therapeutics, there remains an unmet need for treatment of advanced solid tumors. The cGAS-cGAMP-STING pathway plays a pivotal role in innate antitumor immunity processes. IMSA101 is a small molecule analog of cGA…